

## What the CLIP<sup>2</sup> Lille offers you:

Dedicated structures to promote early clinical trials in collaboration with industrial partners.

Access to a population of 6 million inhabitants and more beyond the North region. Every year, the Lille campus treats more than 20,000 cancer patients.

A network of multidisciplinary, high-level clinicians, certified in Pediatric Oncology.

Reactive and efficient teams for all types of partnership between the CLIP<sup>2</sup> Lille and pharmaceutical companies.

Advanced technological platforms in the largest hospital-university complex of Europe.



## The CLIP<sup>2</sup> Lille: a structured team

The CLIP<sup>2</sup> Lille is led by a team of coordinators specialized in all fields of oncology:



Pr Nicolas PENEL  
Medical Oncologist



Pr Laurent MORTIER  
Onco-dermatologist



Pr Thierry FACON  
Hematologist



Pr Alexis CORTOT  
Onco-pulmonologist



Dr Anne-Sophie DEFACHELLES  
Onco-pediatrician



Dr Brigitte NELKEN  
Pediatric Onco-hematologist

Direction de la Communication du CHU de Lille - Mai 2019

# CLIP<sup>2</sup> Lille

## The gateway to early phase clinical trials in oncology



Quality

Expertise

Efficiency

Innovation

For more information, please contact the CLIP<sup>2</sup> project leader:  
**Aurore Acroute - [aurore.acroute@chru-lille.fr](mailto:aurore.acroute@chru-lille.fr)**



Centre Oscar Lambret



supported by



**The Early Phase clinical trial Centre (CLIP<sup>2</sup>) of Lille** has been first certified after a national competitive bid by the French National Cancer Institute (INCa) in 2015 and renewed for 5 years in 2019.

The CLIP<sup>2</sup> Lille brings together on a single site in the North of France the **Oscar Lambret Comprehensive Cancer Centre (COL)** and the **Lille University Hospital Center (CHU)**. Both are recognized as the Regional Reference Cancer Centre with integrated resources and expertise to provide patients of all ages with comprehensive care.

The CLIP<sup>2</sup> Lille promotes early clinical trials in Oncology, strengthens the trial quality and develops bench-to-bedside transition.

## A quality-dedicated structure for early clinical research

The CLIP<sup>2</sup> Lille is specialized in early phase clinical trial with dedicated structures and a team of highly skilled nurses and clinical research assistants.

**For phase I trials**, the Clinical Investigation Centre of the Lille University Hospital Centre and the Clinical Research Unit of the Oscar Lambret Centre comprise a total of **27 beds and chairs** and a fully equipment for the administration and monitoring of anticancer drugs.

**For phase II trials**, the CLIP<sup>2</sup> Lille associates partner departments on the two sites, including pediatric or hematologic departments.

## A renowned medical expertise in oncology

The CLIP<sup>2</sup> Lille is renowned for its excellence in medical research and innovative approach. The Lille University Hospital Centre and the Oscar Lambret Centre have complementary activities. Among the investigators, the CLIP<sup>2</sup> Lille team includes some key leaders of opinion in all the domains of Oncology.

French National Cancer Institute - labeled for early clinical trials in :



- Adult patients (both hematological disease and solid tumors)
- Children (both hematological and solid tumors)

## FOCUS - The CLIP<sup>2</sup> Lille expertise in pediatric oncology:

The CLIP<sup>2</sup> Lille is one of the seven French sites certified by the INCa for its expertise in the management of early clinical trial in the very specific domain of Pediatric Oncology, and provides specific structures and skilled teams for children's treatment.

The CLIP<sup>2</sup> Lille, via the Oscar Lambret Centre, has been **certified by the European consortium ITCC** (Innovative Therapy for Children with Cancer) since 2014.

The CLIP<sup>2</sup> in 2017:



## 2019-2024: innovative perspectives

Three themes have been identified as priorities for the years to come:

1. CART-cells and cellular therapies
2. Molecular tumor board
3. Combination of innovative therapy with radiation therapy

## A reactive and efficient organization

As a reference centre, the Lille campus has an expertise in international partnerships. The CLIP<sup>2</sup> Lille relies on skilled teams in clinical trials regulation and with expertise in legal and financial fields.

Quality-assurance is an essential concern for our structure. Clinical research assistants manage more than 10 audits and inspections on the two sites every year.

The CLIP<sup>2</sup> Lille organization's strengths:

- A single point of contact between sponsors and investigators, via the **CLIP<sup>2</sup> project leader**.
- Possibility for the sponsors to open only one of the two centres with **the potential recruitment of the two centres**.
- Procedures to direct patients from the two sites toward the selected investigator for greater visibility and efficiency.
- Use of the "contrat unique".

## Innovation as a priority

As a comprehensive research centre, the CLIP<sup>2</sup> Lille aims to develop collaboration between scientists and clinicians in order to increase translational advances from basic science into innovative patient care.

The CLIP<sup>2</sup> Lille access to advanced technology platforms:

- A certified tumor bank,
- The Regional Pathology Centre,
- The Regional Molecular Biology of Cancers Platform,
- Molecular oncogenetic laboratories,
- A medical Imaging / Radiation platform with advanced technological equipment.